Grufity logo
Grufity logo

Latest DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Stock Portfolio

$9.59Billion | No. of Holdings #72

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Performance

2026 Q2+14.71%
YTD+16.55%
2025+33.28%

About DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) and 13F Hedge Fund Stock Holdings

DEERFIELD MANAGEMENT COMPANY, L.P. is a hedge fund based in New York, NY. On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, DEERFIELD MANAGEMENT COMPANY, L.P. reported an equity portfolio of $9.6 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of DEERFIELD MANAGEMENT COMPANY, L.P. are NUVL, RVMD, PRAX. The fund has invested 22.2% of it's portfolio in NUVALENT INC and 4.7% of portfolio in REVOLUTION MEDICINES INC. <br><br> The fund managers got completely rid off CATALYST PHARMACEUTICALS INC (CPRX), NEUROCRINE BIOSCIENCES INC (NBIX) and DAY ONE BIOPHARMACEUTICALS I (DAWN) stocks. They significantly reduced their stock positions in VERACYTE INC (VCYT), INSPIRE MED SYS INC (INSP) and INDIVIOR PHARMACEUTICALS INC. DEERFIELD MANAGEMENT COMPANY, L.P. opened new stock positions in MINERALYS THERAPEUTICS INC, BOSTON SCIENTIFIC CORP (BSX) and CHEMED CORP NEW (CHE). The fund showed a lot of confidence in some stocks as they added substantially to GENMAB A/S (GMAB), TYRA BIOSCIENCES INC (TYRA) and IDEAYA BIOSCIENCES INC (IDYA).
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$9.59Billion
  as of Aug 14, 2026

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Annual Return Estimates Vs S&P 500

Our best estimate is that DEERFIELD MANAGEMENT COMPANY, L.P. made a return of 14.71% in the last quarter. In trailing 12 months, it's portfolio return was 58.79%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
revolution medicines inc251,681,000
celcuity inc113,780,000
mineralys therapeutics inc106,787,000
boston scientific corp56,124,200
parabilis medicines inc51,474,900
avalyn pharmaceuticals inc24,064,500
odyssey therapeutics inc19,573,300
alamar biosciences inc16,254,000
New stocks bought by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

Additions

Ticker% Inc.
genmab a/s178
tyra biosciences inc85.25
ideaya biosciences inc77.42
biomarin pharmaceutical inc56.52
structure therapeutics inc41.41
belite bio inc17.49
dianthus therapeutics inc10.35
pharvaris n v8.00
Additions to existing portfolio by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

Reductions

Ticker% Reduced
veracyte inc-86.09
neogenomics inc-82.06
inspire med sys inc-52.03
indivior pharmaceuticals inc-46.77
cogent biosciences inc-44.65
sionna therapeutics inc-29.85
centene corp del-17.17
celcuity inc-15.34
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) reduced stake in above stock

Sold off

Ticker$ Sold
mirum pharmaceuticals inc-209,440,000
enhabit inc-66,895,700
catalyst pharmaceuticals inc-97,643,500
day one biopharmaceuticals i-79,823,900
compass therapeutics inc-19,075,700
taysha gene therapies inc-12,168,100
neurocrine biosciences inc-80,361,400
kymera therapeutics inc-46,739,800
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) got rid off the above stocks

Sector Distribution

DEERFIELD MANAGEMENT COMPANY, L.P. has about 81.7% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare81.7
Others17.6

Market Cap. Distribution

DEERFIELD MANAGEMENT COMPANY, L.P. has about 20.8% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • LARGE-CAP
  • UNALLOCATED
  • SMALL-CAP
Category%
MID-CAP51.7
LARGE-CAP20.8
UNALLOCATED17.6
SMALL-CAP9.5

Stocks belong to which Index?

About 65.7% of the stocks held by DEERFIELD MANAGEMENT COMPANY, L.P. either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
  • S&P 500
Index%
RUSSELL 200055.3
Others34.3
S&P 50010.4
Top 5 Winners (%)%
HUM
humana inc
129.1 %
RVMD
revolution medicines inc
89.1 %
CNC
centene corp del
87.8 %
TOI
the oncology institute inc
76.9 %
MNPR
monopar therapeutics inc
69.0 %
Top 5 Winners ($)$
NUVL
nuvalent inc
363.1 M
RVMD
revolution medicines inc
211.1 M
CNC
centene corp del
170.1 M
LEGN
legend biotech corp
85.4 M
VTRS
viatris inc
47.9 M
Top 5 Losers (%)%
EMBC
embecta corp
-63.1 %
LRMR
larimar therapeutics inc
-32.2 %
bridgebio oncology therapeut
-14.9 %
PFE
pfizer inc
-14.3 %
spyglass pharma inc
-14.1 %
Top 5 Losers ($)$
LRMR
larimar therapeutics inc
-51.6 M
UTHR
united therapeutics corp del
-23.4 M
AHCO
adapthealth corp
-17.0 M
CELC
celcuity inc
-15.1 M
EMBC
embecta corp
-14.1 M

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD MANAGEMENT COMPANY, L.P. has 72 stocks in it's portfolio. About 47.9% of the portfolio is in top 10 stocks. LRMR proved to be the most loss making stock for the portfolio. NUVL was the most profitable stock for DEERFIELD MANAGEMENT COMPANY, L.P. last quarter.

$9.59BTotal Value
95.00Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ADAG
Adagene Inc

Adagene Inc

ADAG
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s holding in Adagene Inc over time
0.12%2,666,670
$11.20M
0.12%
new position
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s holding in Belite Bio Inc over time
0.57%357,199
$55.00M
0.57%
increased 17.49 percentadded